Introducing C6H12O6NTROL™ Software

news-img

2009 – Abstract presented by Dr. DeJournett at Society Critical Care Medicine meeting on potential functionality of Artificial Intelligence based glucose controller.

2010 – Review article on how the native glucose system works published by Dr. DeJournett.
DeJournett, L, Essential Elements of the Native Glucoregulatory System, Which, If Appreciated, May Help Improve the Function of Glucose Controllers in the Intensive Care Unit Setting. J Diabetes Sci Technol 2010; 4(1):190-198.

2013 – Western Carolina University College of Business completes situational analysis of feasibility of introducing an Artificial Pancreas System that was requested by Dr. DeJournett.

2014 – Ideal Medical Technologies incorporated in Delaware.

February 2015 – Ideal Medical Technologies issued U.S. patent rights for ICU based Artificial Pancreas System. US 8,956,321 B2

August 2015 – Ideal Medical Technologies closes seed round of funding.

December 2015 – Ideal Medical Technologies completes successful testing of fully functional closed loop Artificial Pancreas System in animals, at Wake Forest Innovations.

April 2016 – Ideal Medical Technologies issued European patent rights for ICU based Artificial Pancreas System. EP2197521

June 2016 – Dr. DeJournett and son Jeremy DeJournett, whose background is in Electrical Engineering, present results of testing the fully functional prototype of Ideal Medical Technologies Artificial Pancreas System at the 2016 American Diabetes Association meeting.

June 2016 – Dr. DeJournett and son Jeremy DeJournett present results of a large scale simulation study of Ideal Medical Technologies Artificial Pancreas System at the 2016 American Diabetes Association meeting.

June 2016 – Article authored by Dr. DeJournett and son Jeremy DeJournett on large scale simulation testing of Artificial Intelligence based Artificial Pancreas System designed for use in ICU setting published in Journal of Diabetes Science and Technology. This form of testing artificial pancreas systems intended for use in type I diabetics has been accepted by the FDA. http://dst.sagepub.com/content/early/2016/06/14/1932296816653967.abstract

Later 2016 – Ideal Medical Technologies plans to complete first in human testing of working prototype of Artificial Intelligence Based Artificial Pancreas System in an adult cardiac surgery ICU setting.